P3L Peptide Binds CAG-RNA to Rescue Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in addressing the toxicity induced by expanded CAG-repeat RNA molecules in polyglutamine diseases, which contribute to neuronal dysfunction and death through mechanisms independent of polyQ-mediated cytotoxicity.
Innovation Solution
Development of a polypeptide comprising a fragment of the nucleolin protein's RRM domain, specifically P3L, which directly interacts with CAG-repeat RNA to suppress toxicity, potentially used in conjunction with a TAT peptide for enhanced delivery and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-length nucleolin protein is used to inhibit CAG-repeat RNA toxicity, then binding affinity may be sufficient, but the complexity of the device increases and delivery efficiency decreases
Solution Approach 1:
The nucleolin protein is segmented into its functional RRM domain (amino acids 1-100) which contains the CAG-repeat RNA binding capability. This segment is separated from the full-length protein to create a smaller, more manageable therapeutic agent that retains the essential function while reducing complexity and improving delivery.
Solution Approach 2:
The RRM domain (amino acids 1-100) is extracted from the full-length nucleolin protein to create a minimal functional unit. This extracted segment contains the critical RNA binding capability without the unnecessary bulk of the complete protein, thereby improving cellular uptake and reducing device complexity.
2Reliability
If full-length nucleolin protein is used, then binding capability is maintained, but ease of operation and cellular uptake are reduced
Solution Approach 1:
The nucleolin protein is divided into functional segments, with the RRM domain (amino acids 1-100) isolated as the active therapeutic component. This segmentation creates a smaller molecule that can more easily penetrate cellular barriers and be taken up by target cells while preserving the RNA binding function.
Solution Approach 2:
The molecular size parameter is changed by using only the RRM domain (amino acids 1-100) instead of the full-length nucleolin protein. This parameter change improves cellular uptake efficiency and ease of administration while maintaining the essential binding capability through the preserved RRM domain structure.
3Object-affected harmful factors
If previous peptide inhibitors were used, then some toxicity suppression was achieved, but binding affinity was insufficient for effective therapeutic outcome
Solution Approach 1:
The peptide sequence is optimized by using the specific RRM domain sequence (amino acids 1-100 of nucleolin) which has been shown to have superior binding affinity for CAG-repeat RNA compared to previous peptide inhibitors. This parameter change in sequence composition directly improves both binding affinity and therapeutic effectiveness.
Solution Approach 2:
The therapeutic agent is designed as a composite structure combining the RRM domain sequence with a TAT peptide fusion, creating a molecule that has both high affinity for CAG-repeat RNA and enhanced cellular penetration capabilities, thereby overcoming the limitations of previous single-function peptides.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
P3L effectively inhibits expanded CAG-repeat RNA toxicity by binding with higher affinity than previous peptides, rescuing neurodegeneration in both in vitro and in vivo models, and demonstrating low cellular toxicity.
Implementation Method 1
certain fragments of the nucleolin protein (NCL) can directly interact with CAG-repeat RNA and suppress CAG-repeat RNA toxicity
Data Source
AI summary
The present invention provides for a novel peptide and method for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.